In the Claims:

Please amend the claims as follows:

1. (Four times amended) A composition [for use in the healing of wounds with no or at least reduced scarring as compared with healing by natural processes and for the treatment of fibrotic disorders,] comprising TGFβ-3 [with no fibrotic growth factor or] with fibrotic growth factors or fragments thereof present in the composition in a lower proportion to TGFβ-3 than occurs naturally in the wounds or disorders in question, or with such fibrotic growth factors together with antibodies selected from the group which neutralize TGFβ-1, TGFβ-2 or PDGF, all in a pharmaceutically acceptable carrier in an amount effective for healing of wounds with no or at least reduced scarring as compared with healing by natural processes and for the treatment of fibrotic disorders.

17. (Amended) A composition according to claim 1, wherein the carrier comprises a biopolymer, for example collagen[,] or hyaluronic acid, or a polymer of PVC, for contacting or implanting into the wound/fibrotic lesion so as to [allow] provide release of the active agents slowly or quickly and [for] to [be active in situ] provide *in situ* activity.

19. (Amended) A method of inhibiting fibrosis during the healing of wound and other fibrotic diseases, disorders or conditions, comprising administering to a host suffering from tissue wounding or these fibrotic conditions[, at least one non-fibrotic growth factor] an effective amount of a composition including TGFβ-3 or a non-fibrotic fragment thereof (a) with at least one fibrotic growth factor present in the composition in a lower proportion

to such non-fibrotic growth factor than occurs naturally in the wounds or disorders, or (b) with at least one fibrotic growth factor together with at least one anti-fibrotic agent against the fibrotic growth factor, in a pharmaceutically acceptable carrier.

21. (Twice amended) A composition [for use in the healing of wounds with no or at least reduced scarring as compared with healing by natural processes and for the treatment of fibrotic disorders,] comprising [(1)] TGFβ-3 or a non-fibrotic fragment thereof [with no fibrotic growth factor or (2) TGFβ-3] (a) with at least one fibrotic growth factor present in the composition in a lower proportion to such non-fibrotic growth factor than occurs naturally in the wounds or disorders, or (b) with at least one fibrotic growth factor together with at least one anti-fibrotic agent against the fibrotic growth factor, in a pharmaceutically acceptable carrier in an amount effective for healing of wounds with no or at least reduced scarring as compared with healing by natural processes and for the treatment of fibrotic disorders.

Please add the following new claims 23-37:

--23. A method according to claim 19, wherein the composition further comprises FGF.

24. A method according to claim 19, wherein the composition comprises anti-fibrotic agents.

25. A method according to claim 19, wherein the anti-fibrotic agents include antibodies to TGFβ-1, TGFβ-2 and PDGF; binding proteins which prevent TGFβ-1, TGFβ-2 and PDGF from binding to their receptors by either binding to the growth factor itself or binding to the receptor; or soluble forms of growth factor receptor or the growth factor binding domains of these receptors or antisense oligonucleotides or ribozymes which act to prevent fibrotic growth factors mRNA translation.

26. A method according to claim 19 wherein the non-fibrotic growth factor or anti-fibrotic agent(s) are present in the composition in an active form.

27. A method according to claim 19, wherein the non-fibrotic growth factor or anti-fibrotic agent(s) are present in the composition in an inactive form.

28. A method according to claim 27, wherein inactivation is by encapsulation.

29. A method according to claim 28, wherein the capsules are degradeable by an external stimulus to release the active form when required.

30. A method according to claim 29, wherein the external stimulus includes UV light, ultrasound, in vivo enzymes or heat.

31. A method according to claim 27, wherein inactivation is by the molecular addition of a binding molecule which is detachable when required by an external stimulus including UV light, ultrasound, in vivo enzymes or heat.

32. A method according to claim 19, wherein the non-fibrotic growth factor is present in an inactive form, for example, as a precursor, and is activated upon contact with tissue containing the natural cleavage enzymes required to convert the precursor into its active form.

33. A method according to claim 19, wherein the carrier comprises a neutral sterile cream, gel, aerosol or powder for topical application.

34. A method according to claim 19, wherein the carrier comprises a patch or a sterile dressing or an absorbable dressing for topically covering a wound.

35. A method according to claim 19, wherein the carrier comprises a sterile solution for irrigation, injection or inhalation.

36. A method according to claim 19, wherein the carrier comprises a tablet, capsule, and the like, for enteral administration.